Open Label Trial to Assess Iressa in Prostate Cancer Patients

• Status: Completed
• Trial end date: 2003-02-01
• Target enrollment: 0
• Participant gender: All

Summary

A study to assess the activity of Iressa in patients who's prostate cancer has recurred, and who have rising PSA levels

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: AstraZeneca
• Treatments: Gefitinib

Criteria

Inclusion Criteria:

• Prostate cancer diagnosis

• no evidence of metastasis

• Age 18 or older

Exclusion Criteria:

• Prior chemotherapy for recurrent prostate cancer

• Radiotherapy completed within 28 days of starting the study

• Incomplete healing from prior cancer or other major surgery